The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

The Tobias-Lechleiter Institute for Clinical Innovation will serve as a hub for "groundbreaking" disease detection and ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Pharma giant Eli Lilly is planning a $5.9 billion investment for a massive pharmaceutical manufacturing facility in McCord ...

Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly said the revision reflects a $1.57 billion deal charge recorded in the first quarter, which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics.

“We will remain in the anti-diabetic space in biologics and focus on it," he said, sharing examples of top pharma companies such as Eli Lilly and Novo Nordisk withdrawing insulin brands Basaglar and ...